Ceryvyn Therapeutics Limited

OTCPK:OPTE.Y Stock Report

Market Cap: US$13.3m

Ceryvyn Therapeutics Past Earnings Performance

Past criteria checks 4/6

Ceryvyn Therapeutics's earnings have been declining at an average annual rate of -9.8%, while the Biotechs industry saw earnings growing at 36.2% annually. Revenues have been growing at an average rate of 7.3% per year.

Key information

-9.76%

Earnings growth rate

3.19%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate7.27%
Return on equity880.72%
Net Margin-1,476,212.82%
Last Earnings Update31 Dec 2025

Recent past performance updates

No updates

Recent updates

Seeking Alpha • Jan 30

Opthea: Small Australian Company Aiming To Upend The Wet AMD Market

Summary Opthea's lead compound, sozinibercept, targets VEGF-C/D and is in Phase 3 trials for wet AMD, showing promising Phase 2b results. Wet AMD treatments like Lucentis and Eylea have limitations; sozinibercept aims to improve efficacy by targeting a broader VEGF family. Financially, Opthea has a market cap of $797mn and a cash runway of 4-5 quarters, but faces transparency and dilution risks. Despite compelling data, market entry challenges and low trading volume make me cautious; I await topline data before investing. Read the full article on Seeking Alpha
Seeking Alpha • Nov 07

Opthea Limited: Major Catalyst In Early 2025 For Complementary Eye Disease Candidate

Summary Opthea is a clinical-stage biotech firm developing Sozinibercept, targeting VEGF-C and VEGF-D for wet AMD, with Phase 3 results due in 2025. The wet AMD market is lucrative, but the challenge lies in the patient's willingness to receive two intravitreal injections for potentially better outcomes. Phase 2b results were promising, but Phase 3 studies face uncertainties due to different standards of care and longer study durations, amongst other reasons. Opthea's financial pressure and competitive landscape make it a risky investment; I assign a "Hold" rating pending Phase 3 outcomes. Read the full article on Seeking Alpha
Seeking Alpha • Aug 30

Opthea GAAP EPS of -$0.26 misses by $0.03

Opthea press release (NASDAQ:OPT): FY GAAP EPS of -$0.26 misses by $0.03. As of June 30, 2022, Opthea had cash, cash equivalents and short-term investments of $44.6 million.
Seeking Alpha • Aug 15

Opthea receives $170M in non-dilutive financing for OPT-302 in wet AMD

Opthea (NASDAQ:OPT) entered into a non-dilutive financing transaction for up to $170M from investment funds working with Launch Therapeutics to finance and advance the ongoing Phase 3 clinical trials and pre-commercialization activities of OPT-302 for wet age-related macular degeneration. Launch Tx is the recently formed development company backed by funds managed by global investment firm Carlyle and its life sciences franchise, Abingworth. Under agreement terms, the funds managed by Carlyle and Abingworth, in collaboration with Launch Tx, will commit $120M in three installments at fixed time points and retain an option to commit another $50M. Opthea retains full worldwide commercial rights for OPT-302 and has the option to prepay its obligations in full at any time. "This strategic transaction is expected to fund us through Phase 3 topline data expected in mid-2024 and strengthens our strategic position to maximize the value of OPT-30," CEO Dr Megan Baldwin commented.

Revenue & Expenses Breakdown

How Ceryvyn Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:OPTE.Y Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2502972583
30 Sep 2502434137
30 Jun 250-24744192
31 Mar 250-33142228
31 Dec 240-39338251
30 Sep 240-34530245
30 Jun 240-33023264
31 Mar 241-29720253
31 Dec 231-24516227
30 Sep 231-24125220
30 Jun 231-21432193
31 Mar 230-20537177
31 Dec 220-19440159
30 Sep 220-17635146
30 Jun 220-13426114
31 Mar 220-1002282
31 Dec 210-792160
30 Sep 210-712048
30 Jun 210-601835
31 Mar 210-511431
31 Dec 200-401025
30 Sep 200-30922
30 Jun 200-16717
31 Mar 200-17720
31 Dec 190-17622
30 Sep 190-19627
30 Jun 190-21531
31 Mar 190-19531
31 Dec 180-17432
30 Sep 180-17528
30 Jun 180-17525
31 Mar 180-16519
31 Dec 170-15513
30 Sep 170-1159
30 Jun 170-655
31 Mar 170-755
31 Dec 160-755
30 Sep 160-744
30 Jun 160-744
31 Mar 160-544
31 Dec 151-434
30 Sep 151-535

Quality Earnings: OPTE.Y has high quality earnings.

Growing Profit Margin: OPTE.Y became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: OPTE.Y has become profitable over the past 5 years, growing earnings by -9.8% per year.

Accelerating Growth: OPTE.Y has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: OPTE.Y has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (54.5%).

Return on Equity

High ROE: OPTE.Y's Return on Equity (880.7%) is considered outstanding.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/07 03:59
End of Day Share Price 2026/07/07 00:00
Earnings2025/12/31
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ceryvyn Therapeutics Limited is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Elyse ShapiroCanaccord Genuity
John SavinEdison Investment Research
Chris CooperGoldman Sachs